Announcement PDF BP8: A Health and Energy Technology Company INVESTOR DECK BPH GLOBAL LIMITED (ASX:BP8) www. bp8global.com Offer Information and Disclaimer This investor presentation (the “presentation”) is for informational purposes only and does not constitute an offer to sell, a solicitation of an offer to buy, or a recommendation to purchase any equity, debt or other financial instruments of BPH Global Limited (BP8). The presentation has been prepared to assist parties in making their own evaluation and for no other purpose. Parties should further carry out their own due diligence. It is not intended to form the basis of any investment decision or any other decisions. No Representation or Warranty Eligible Recipients No representation or warranty, express or implied, is or will be given by BP8 or any of its respective affiliates, directors, officers, employees or advisers or any other person as to the accuracy or completeness of the information in this presentation or any other written, oral or other communications transmitted or otherwise made available to any party in the course of its evaluation, and no responsibility or liability whatsoever is accepted for the accuracy or sufficiency thereof or for any errors, omissions or misstatements, negligent or otherwise, relating thereto. This presentation does not purport to contain all of the information that may be required to evaluate a possible investment opportunity with respect to BP8, and does not constitute investment, tax or legal advice. This presentation is provided to you as an investor to whom an offer document is not required to be given, and no registration, lodgement or other formality is required, in connection with an offer of securities. In accepting this presentation, you warrant that you are an investor within the scope of this paragraph and that you accept this presentation on the basis set out in this notice. This presentation is not, and does not constitute, or form any part of, an offer to sell or the solicitation, invitation or recommendation to purchase any securities in the United States and neither this presentation nor anything contained herein shall form the basis of any contract or commitment. The distribution of this presentation may be restricted by law. Persons who come into possession of this presentation should seek advice and observe any such restrictions. Any failure to comply with such restrictions may constitute a violation of applicable securities laws. The recipient also acknowledges and agrees that the information contained in this presentation is preliminary in nature and is subject to change, and any such changes may be material. BP8 disclaims any duty to update the information contained in this presentation. This presentation may contain trademarks, service marks, trade names and copyrights of other companies, which are the property of their respective owners. Solely for convenience, some of the trademarks, service marks, trade names and copyrights referred to in this presentation may be listed without the TM, SM© or ® symbols, but parties assert, to the fullest extent under applicable law, the rights of the applicable owners, if any, to these trademarks, service marks, trade names and copyrights. No Offer or Solicitation This presentation shall not constitute a solicitation of a proxy, consent or authorization with respect to any securities. This presentation shall also not constitute an offer to sell or the solicitation of an offer to buy any securities. No offer, sale or solicitation of any securities shall be made in any jurisdiction in which such offer, sale or solicitation would be prohibited. BP8 does not provide investors with personal advice that any investment made will be suitable for the investor’s personal circumstances or investment objectives. No representation or warranty is given by BP8 that any investment with respect to BP8 is suitable for the investor or that it will meet the investor’s investment objectives. Forward Looking Statements This presentation contains “forward-looking statements”. These statements are based on management’s current expectations and beliefs, as well as on a number of assumptions concerning future events. Forward-looking statements are subject to known and unknown risks and uncertainties, many of which are outside of our control and all of which could cause actual results to differ materially from the results expressed or implied in the forward-looking statements. BP8 may not actually achieve the plans, intentions or expectations disclosed in these forward-looking statements and the forward-looking statements should not be unduly relied upon. We do not undertake any obligation to update forward-looking statements following the date this presentation is made. Any industry, market or other, similar data have been compiled from sources thought to be reliable, but have not been verified, and no assurance can be made as to their accuracy. Risks Please refer to Appendix 1 for Key Risks 2 Investment Highlights BP8 is a diversified biotechnology company focused on the health and energy industries. New management driving business development with focus on revenue growth Primary focus on seaweed: Cultivation and acquisition of raw seaweed for sale to SE Asian markets Production of bio-stimulant products for sale to Indian agricultural markets R&D - extraction of nutraceuticals, minerals and hydrogen to facilitate the commercialisation of seaweeds : • • • sale of seaweed-based nutraceuticals and pharmaceutical ingredients to the food, nutrition, healthcare, health supplements, cosmetics and personal care industries sale of extracted seaweed-based rare earth minerals and nano minerals to the battery & minerals industries sale of seaweed-derived hydrogen to the energy supply industry Market focus: India, Southeast Asia and China 3 Business Model: Seaweed Sale of Raw Seaweed & Production & Sale of Bio-stimulant SALES CHANNELS Cultivation & harvesting/ acquisition of raw seaweed Processing of raw seaweed to produce bio-stimulant products Sales to Indian agriculture industry to promote crop growth and crop nutrient content SALES CHANNELS Sales of raw seaweed to South-East Asian-based food markets 4 Indonesian Seaweed Project Announcement of establishment of Indonesianbased, seaweed focused joint venture business Development of seaweed-based bio-stimulant products for sale to India JV to be owned & operated by a new wholly owned subsidiary of BP8 Indicative of initial steps In the Company’s pivot towards the Indian market Joint venture partners already contributing assets to the JV Business Development driver Commercialisation potential Initial focus on revenue generation from sales of raw seaweed 5 Enormous Potential Indonesian territorial waters: Sixth-largest exclusive economic zone in the world with 6,159,032 km2 . 81407 km coastline The Siboga Expedition identified 555 species. 56 species used for food and medicine 6 The global commodity-based seaweed industry; 36 million tons worth 18-28 billion dollars (FAO, 2021, markets 2024) 6-8% 97% 10.8% Growth per year cultivated (about 1 million tons wild harvest) CAGR (20222028) Green (about 1200 species) Brown (about 1750 species) Red (about 6000 species) Seaweed Cultivation at a global scale (Buschmann et al., 2017, FAO 2023) 7 Trucking the Raw Seaweed for processing in Warehouse Seaweed Business Sourcing: • Co-operative farming with coastal communities • Land based farms using race pools near the sea • Collectors and Village Co-operatives • Corporate Farming Check Quality Parameters for Moisture, debris and foreign matter At the warehouse Drying - Sorting and Pressure packing in bales. Dispatch to Local Carrageenan and Agar Factories Export Destinations: China, Philippines, India , Vietnam , France 8 US$23 billion Food and food ingredients used in products US$3 US$2 billion Hydrocolloids billion Others (biostimulant /plastics etc;) Total value US$20-30 billion (market insight 2024) 9 Other Markets for Seaweed Pharmaceuticals Nutraceuticals Biostimulants Alternative Proteins 10 Farm Plot Metrics Our Plot Metrics • Length of one plot = 100 m • Total no of 10 metre tubes = 100 • Size of one plot = 1000 sq. metres • Anchoring involved in one plot = 150 kgs x 16 • Labour involved in establishing a plot = 8 ladies + 10 gents • 2 days work 11 Farming kappaphycus will reduce the pressure on wild farming of other species. 12 • CO2 up take through seawater plus de-acidification oceans (coral reef protection, biodiversity, food) • P&N recycling, (run off from land or other aquaculture activities) • High in Potassium and other important minerals • Excellent source for fertiliser, animal feed and valued added materials and bioactives • Circular economy and nutrient recycling • Social impact coastal rural areas CARBON CAPTURE COMMUNITY DEVELOPMENT 13 PRINCIPAL R&D GOALS Extraction of seaweed-based nutraceuticals and pharmaceutical ingredients to infuse into food, nutrition, healthcare, health supplements, cosmetics and personal care products Extraction of seaweed-based critical minerals for the sale into the battery & minerals industries R&D Program Highlights Sale of seaweed-derived bio-hydrogen to the energy supply industry R&D activity that is focused on value-added products that attract higher sales margins 14 Business Model: Seaweed Extraction of Nutraceuticals for use in the Food Industry POST HARVEST PROCESSING Local Germplasm Seedbank Utilization of Precision Cultivation Systems Cultivation in clean seawaters HARVESTING Employ Key Downstream Nutraceutical Extraction Technology and. and Block Chain technology to extract and trace nutraceuticals MULTIPLE SALES APPLICATIONS In food, health and cosmetics industries for products incorporating seaweed-derived nutraceuticals 15 Business Model: Seaweed Extraction of Minerals for use in the battery industry POST HARVEST PROCESSING Local Germplasm Seedbank Utilization of Precision Cultivation Systems Cultivation in polluted/ mineral-rich seawaters HARVESTING Employing Key Downstream Mineral Extraction Technology and Block Chain technology to extract and trace strategic minerals for use in the battery industry MULTIPLE SALES APPLICATIONS To the battery technology and manufacturing industries that are using seaweed-derived chemicals and minerals to improve battery performance and life span to enable production on a commercial scale 16 Business Model: Seaweed Extraction of Bio-hydrogen for use in the energy industry POST HARVEST PROCESSING Local Germplasm Seedbank Utilization of Precision Cultivation Systems Cultivation in seawater HARVESTING Employing Key Downstream Fermentation and Extraction Technologies to extract hydrogen/other bio-gases MULTIPLE SALES APPLICATIONS In the energy industries for use as a clean energy resource 17 Business Model: Seaweed Recognition, qualification and issue of Blue Carbon Credits 1 2 3 Seaweeds and seagrasses up to four times more effective in capturing carbon Yet no accreditation scheme for blue carbon credits The problem is that many seaweeds do not store carbon long term 4 7 6 5 Development of blue credit accreditation protocols Application of block chain technology to demonstrate capture of carbon Fibrous seaweeds and building materials Accreditation challenge: prove long term storage 18 Business Model: Bird’s Nest Sale of Bird’s Nest products in China Tobacco’s outlets in the City of Guangzhou in China Delivered to BP8’s China subsidiary Foshan Gedishi Biotechnology Co Ltd Bird’s nest products sourced from Malaysian suppliers Sale of Bird’s Nest products in China via sales agreements with key opinion leaders (KOLs) to maximise sales opportunities on Douyin (the Chinese equivalent of TikTok) Supply agreements with major Chinese banks to supply bird’s nest products for corporate gift giving 19 Capital Structure ASX Code Security Number BP8 ORDINARY SHARES 396,641,479 BP8O LISTED OPTIONS EXP 07/07/2027 at $0.05 44,166,876 BP8AA OPTIONS EXP 5/12/2028 at $0.05 1,020,000 BP8AA OPTIONS EXP 16/12/2024 at $0.05 100,000 BP8AA OPTIONS EXP 18/12/2025 at $0.05 1,000,000 BP8AA OPTIONS EXP 11/12/2026 at $0.02 115,877,226 BP8AI OPTIONS EXP 09/04/2026 at $0.085 5,000,000 BP8AJ OPTIONS EXP 01/11/2027 at $0.25 5,000,000 BP8AN OPTIONS EXP 28/02/2027 at $0.10 1,000,000 BP8AM OPTIONS EXP 28/02/2027 at $0.085 1,000,000 BP8AP OPTIONS EXP 28/02/2025 at $0.125 3,000,000 BP8AQ OPTIONS EXP 28/02/2025 at $0.25 1,500,000 BP8AR OPTIONS EXP 28/02/2025 at $0.375 500,000 BP8AO OPTIONS EXP 28/02/2027 at $0.05 100,000 BP8AU OPTIONS EXP 01/09/2025 at $0.09 5,533,338 BP8AA OPTIONS EXP 11 Dec 2026 @$0.02 5,816,828 20 Directors Paul Stephenson Yanhua Huang Matthew Leonard Non-executive Chair Non-executive Director Managing Director/CEO Mr Paul Stephenson was a partner in the Sydney Office of HWL Ebsworth Lawyers (HWLE) for thirteen years before retiring from the partnership in 2017. Mr Stephenson remains a consultant with HWLE and is also a foreign (Australian) lawyer consultant with Israeli law firm Afik & Co. Mr Stephenson specialises in public and private equity fundraising, initial public offerings, backdoor listings and reverse mergers (both in Australia and the United States), and mergers and acquisitions involving both private and listed companies. Mr Stephenson has experience in a large number of industry sectors including resources, oil and gas, retailing, financial markets, and cannabis. Mr Stephenson has acted on many cross-border transactions and has expertise in equity capital markets and M&A transactions involving the USA, UK, China, Indonesia, Singapore, Malaysia, Hong Kong and Israel. Mr Huang is a seasoned businessman and management consultant with almost 20 years of experience, accumulated from working in management consulting firm Accenture and audit firm KPMG, and also from managing companies in the construction, manufacturing and trading industries. Mr Huang graduated from the Lancaster University with a Bachelor degree and from the London School of Economics with a Master’s degree. Mr Leonard is an accomplished and internationally proven business development professional. With over 12 years of outstanding record of achievement in demanding, complex and highly competitive markets. He possesses expertise across advertising, marketing and media event management sector, with recent focus on linking opportunities with high-net-worth individuals throughout Asia. Mr Leonard is also a member of Golden Venture Capital which provides corporate advisory and consultancy services. In this role, Mr Leonard has assisted a number of companies to raise capital throughout Asia and Australia. Francesco Cannavo Deepak Jha Executive Director Managing Director - Indonesia Mr Cannavo is an experienced public company director with significant business and investment experience working with companies operating across various industry sectors. Mr Cannavo is the founder of Golden Venture Capital, a corporate advisory firm based out of Melbourne, Australia. He has been instrumental in assisting many listed and unlisted companies achieve their growth potential by providing strategic advice on raising investment capital and completing strategic acquisitions. He is an entrepreneur with a strong network of investors and industry contacts in the public company sector in Australia and throughout the AsiaPacific region. He has extensive experience in capital raisings, investment activities and IPOs. With over 20 years of experience across Indonesia’s trading, mining, manufacturing, and investment sectors, I specialize in driving growth in challenging and emerging markets. As a board member and shareholder at Mitra Agro Global and other ventures, I’ve successfully led large-scale projects with a focus on sustainable, profitable growth. My leadership approach emphasizes building resilient teams and strategic partnerships to maximize long-term value. An advocate for the Blue Economy, I actively promote sustainable seaweed farming and ULVA cultivation in collaboration with UN GQSP Program among Indonesia's coastal communities, aligning investor returns with environmental impact. 21 Reinvigorated management driving a commercially sensible business plan with a pivot towards India Deep expertise in sourcing and cultivating seaweed and the extraction of rare earth minerals, nano minerals and nutraceuticals from seaweed BPH GLOBAL LIMITED (ASX:BP8) www. bp8global.com • Chairman: Paul Stephenson • Email: paul.stephenson1@icloud.com • CEO: Matthew Leonard • Email: matthew@goldenventurecapital.com Business focus on sales into high value markets New Business Opportunities sought and welcomed to grow the Company’s operations and revenue Authorised by the Board of Directors 22 Appendix 1: Key Risks There are specific risks which relate directly to the Company’s activities. In addition, there are other general risks, many of which are largely beyond the control of the Company and the Directors. The risks identified in this section, or other risk factors, may have a material impact on the financial performance of the Company and the market price of the Company’s securities. The following is a summary of the more material matters to be considered and should be read in conjunction with specific matters referred to in the Company’s announcements and reports. However, the summary is not exhaustive and potential investors should consult their professional advisors before deciding whether to apply for securities in the Company. Business development and commercialisation in the food, nutrition, healthcare, health supplements, cosmetics and personal care induThe Company is focused on producing foods and products which deliver Traditional Chinese Medicine (TCM)-based health outcomes and the development of technologies to enable the extraction of hydrogen and minerals from seaweed for use in the energy and battery industries. Regarding TCM products, the Company focuses on the research & development (R&D), production and commercialisation of bird’s nest and plant-based products, including seaweed and sea plants and hemp, to produce sustainable bird’s nest and plant-based protein foods and nutraceutical and pharmaceutical ingredients (including CBD extracted from Hemp) for utilisation stries. Regarding the energy and battery industries, the Company focuses its R&D on the extraction of hydrogen and minerals from seaweed, leveraging its technologies developed for the extraction of nutraceuticals from seaweed. There can be no guarantee that the resulting products or extracted hydrogen and minerals will be commercialised, will be competitive in their respective markets, or will perform satisfactorily to their intended application. Funding Any inability of the Company to obtain additional funding as required, including under the proposed capital raising, would have a material adverse effect on the Company’s business, its financial condition and performance and its ability to continue as a going concern. Accordingly, there is a material uncertainty that may cast doubt on the Company’s ability to continue as a going concern. Should the Company not be able to continue as a going concern, it may be required to realise its assets and discharge its liabilities other than in the ordinary course of business, and at amounts that differ from those stated in the Company’s financial statements. Research and development risk In order to remain competitive, the Company intends to continue to undertake research and development. The Company makes no representation that any of its research into or development of its technologies and products will be successful or that its technologies will be developed into products that are commercially exploitable. Intellectual Property Risks The Company will give consideration to whether it will pursue patent protection in Singapore and other jurisdictions in relation to technologies it develops. However, there is no guarantee that any future patent applications filed by the Company will not infringe competitor patents or that any such patent applications will be granted by authorities in key jurisdictions, given that patents on similar subject matter may have been granted. Regulatory Changes in relevant taxes, legal and administration regimes, accounting practice and government policies may adversely affect the financial performance of the Company. Reliance on key management The responsibility of overseeing the day-to-day operations and the strategic management of the Company depends substantially on its senior management and its key personnel. There can be no assurance given that there will be no detrimental impact on the Company if one or more of these employees cease their employment. Supply of Raw Materials The Company may depend on the supply of raw materials to carry on elements of its business. Such supply may be disrupted because of weather, transportation and other matters outside the Company’s control. Product liability The Company provides products for use in TCM and food products to deliver TCM-based health benefits, which are used and/or consumed by humans for therapeutic and other purposes. If the Company’s product(s) causes damage or loss of life, claims may be made against the Company that it has supplied defective products. Armed conflicts The market price of the Company’s Shares and Options may be adversely affected in the short to medium term by the economic uncertainty caused by the Ukraine conflict and the conflict in the Middle East. Sovereign Risk The Group’s operations will continue to include a focus on markets in China and South East Asia, including but not limited to Singapore and Malaysia. Possible sovereign risks associated with operating in China and these South East Asian nations include, without limitation, changes in the terms of legislation, changes to taxation rates and concessions and changes in the ability to enforce legal rights. Any of these factors may, in the future, adversely affect the financial performance of the Company and the market price of the Company’s Shares and listed Options. 23